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1 Background 
1.1 Drug  
Generic/Brand name/ATC code: Erlotinib/Tarceva®/L01XE0 
Developer/Company: Roche Pharma AG 
Description: 
Erlotinib, a quinazoline derivative, is a tyrosine kinase inhibitor (TKI) of 
the epidermal growth factor receptor (EGFR). Since EGFR controls func-
tions such as proliferation and apoptosis [1], enhanced activation of EGFR 
leads to tumour angiogenesis and tumour growth. Activating EGFR muta-
tions are present in about 15% of patients suffering from non-small cell lung 
cancer (NSCLC) and several mechanisms can cause an improper activation 
of the EGFR, including EGFR gene mutation, EGFR protein overexpression 
or an increased gene copy number [2]. Even though different methods are 
available to assess EGFR protein expression and EGFR gene copy number 
such as immunohistochemistry (IHC) or fluorescence in situ hybridisation, 
EGFR somatic mutation testing is the preferred method to identify eligible 
patients for erlotinib therapy [3-5]. The most frequent EGFR mutations are 
the exon 19 deletion and the L858R point mutation in exon 21 [1, 2] which 
can be detected by several tests [6]. 
Administration: 150 mg erlotinib are administered orally once daily until 
disease progression or unacceptable toxicity.  
2 Indication 
Erlotinib is indicated for the first-line treatment of patients with locally ad-
vanced or metastatic NSCLC with EGFR activating mutations. 
3 Burden of disease 
As NSCLC accounts for about 85% of all lung cancer cases [7] it is one of 
the leading causes of cancer- deaths worldwide. Its primary risk factors are 
first- and second-hand smoke exposition [8]. Men are still more often af-
fected by NSCLC than women, with the majority of patients being diag-
nosed at an age ≥ 65 years [9]. On average, patients are aged 71 years at the 
time of diagnosis of NSCLC.  
Based on the tumour node metastasis (TNM) system which takes character-
istics like tumour size, location, invasion of the surrounding tissue, presence 
of metastasis in the lymph nodes or distant metastasis into account, four 
stages are distinguished. Locally advanced and metastasised NSCLC corre-
sponds to TNM stage III and IV, respectively [10, 11]. NSCLC can be fur-
ther distinguished into two groups: non-squamous carcinomas and 
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squamous carcinomas (25% of lung cancers), the first one comprising large 
cell carcinoma (10% of lung cancers), adenocarcinomas (40% of lung can-
cers) and other, less frequent cell types [8, 12].  
First-line therapy of advanced NSCLC depends on a number of factors, such 
as tumour stage, histo-pathologic subtype, co-morbidities and performance 
status [8, 13]. In addition, due to the development of targeted therapies, 
EGFR mutational status should also be assessed prior to therapy [3]. How-
ever, some guidelines recommend routine testing for EGFR mutations only 
for non-squamous NSCLC (which comprises adenocarcinomas, the most 
frequent histo-pathologic subtype), because EGFR mutations in squamous 
cell carcinomas are present in less than 3.6% of patients [8]. EGFR muta-
tions are also more frequent in women, non-smokers and Asians [13].  
3,600 people died of lung cancer and, about 4,100 new cases of lung cancer 
were diagnosed in Austria in 2008 [14]. Since 85% of these cancers are 
NSCLC of which about 65% [9, 15] can be expected to present with ad-
vanced disease, an estimated 2,260 persons are diagnosed with advanced 
NSCLC per year. Applying estimates of an average frequency of activating 
EGFR mutations (within an Caucasian population about 15%) to these 
numbers would result in about 340 individuals with activating EGFR muta-
tions and thus potentially eligible for treatment with Tarceva®. 
4 Current treatment options 
Systemic treatment options for the first-line therapy for patients with ad-
vanced/metastatic disease (TNM IIIB, IV) are  
 platinum-based chemotherapy: modern regimens are mostly based on 
a platinum compound (cisplatin, carboplatin) in addition to one out 
of numerous other substances (e.g. vinorelbine, paclitaxel, docetaxel, 
gemcitabine, pemetrexed). For neither of these combinations superi-
ority has been established unequivocally, but for patients with non-
squamous histology cisplatin + pemetrexed might be the best treat-
ment option [16]. 
 other chemotherapeutic regimens: due to the toxicity of platinum 
based regimens, other drug combinations can be used (gemcitabine + 
docetaxel/paclitaxel/vinorelbine/pemetrexed, paclitaxel + vinorel-
bine).  
 single agent chemotherapy as first-line treatment is generally used for 
elderly patients or for those with poor performance status.  
 targeted therapies:  
 TKIs (i.e. gefitinib) as mono-therapy. 
 monoclonal antibodies: bevacizumab (licensed) in combination 
with paclitaxel + carboplatin or gemcitabine + cisplatin for pa-
tients with non-squamous NSCLC and cetuximab (not licensed for 
this indication) preferably in combination with cisplatin + vi-
norelbine for patients with EGFR IHC positive metastatic NSCLC 
[3, 16].  
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However, if patients are EGFR mutational status positive, EGFR-TK inhibi-
tors are increasingly used as standard first-line therapy, whereas patients 
with either unknown EGFR status or without EGFR mutation, should re-
ceive chemotherapy doublets, either alone, or in combination with a mono-
clonal antibody (e.g. bevacizumab) [3, 17]. Different administration sched-
ules apply for these regimens, because chemotherapy is generally adminis-
tered for 4-6 cycles and EGFR-TKIs are delivered until disease progression 
or unacceptable toxicity.  
5 Current regulatory status 
In Europe, the European Medicines Agency (EMA) licensed erlotinib for: 
 NSCLC:  
 as mono-therapy for maintenance treatment in patients with locally 
advanced or metastatic NSCLC with stable disease after four cycles 
of standard platinum-based first-line chemotherapy in April 2010. 
 for the treatment of patients with locally advanced or metastatic 
NSCLC after failure of at least one prior chemotherapy regimen. 
 Metastatic pancreatic cancer in combination with gemcitabine as 
first-line therapy in January 2007.  
In July 2011, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a positive opinion recommending an extension of in-
dication for erlotinib as first-line treatment of patients with locally ad-
vanced or metastatic NSCLC with EGFR activating mutations [18].  
In the U.S., the Food and Drug Administration (FDA) has not yet ap-
proved erlotinib for the first-line therapy of NSCLC. However, market 
authorisation was granted for:  
 NSCLC:  
 as maintenance treatment of patients with locally advanced or me-
tastatic NSCLC whose disease has not progressed after four cycles 
of platinum-based first-line chemotherapy. 
 for the treatment of locally advanced or metastatic NSCLC after 
failure of at least one prior chemotherapy regimen.  
 For the first-line treatment of patients with locally advanced, unre-
sectable or metastatic pancreatic cancer, in combination with gemcit-
abine [19]. 
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6 Evidence 
A literature search was conducted on the 7th of November 2011 in four data-
bases (The Cochrane Library, EMBASE, Ovid, CRD Database) yielding 493 
references overall. In addition a hand search was performed including the 
websites of the EMA and the FDA.  
Considered were only those studies which had enrolled patients with activat-
ing EGFR mutations and advanced/metastatic NSCLC, resulting in two 
phase III studies [20-22] of which only one [20] is fully published.  
In addition, one screening study and one pooled analysis are presented 
within this report [23, 24]. Several other studies investigating first-line ther-
apy with erlotinib in patients with NSCLC were identified, but their results 
are not displayed since presence of activating EGFR mutations was not a 
prerequisite for study entry [25-35]. 
6.1 Efficacy and safety - RCTs 
Table 6.1.-1: efficacy of the OPTIMAL trial 
Study title  
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-
cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase III study [20] 
Study identifier NCT00874419, OPTIMAL study, CTONG-0802, ML20981 
open-label, randomised, phase III trial, China Design 
Duration  Enrolment: 12 months 
Median follow-up: 15.6 months 
Primary cut-off date: planned July 2010 but after 10 additional events had 
occurred an  updated analysis was performed in August 2010 
Hypothesis Superiority 
Funding Hoffmann-La Roche 
Intervention (I) 150 mg erlotinib/day orally 
until disease progression or unacceptable toxic effects 
Treatment groups 
Control (C) 1000mg/m2 gemcitabine i.v. (days 1 and 8) + carboplatin (AUC =5] i.v. (day 1 
of a 3-week cycle) up to four cycles  
Progression-free  
survival 
(primary outcome) 
PFS time from the date of randomization to the date of first documenta-
tion of progressive disease or date of death from any cause, which-
ever comes first. Disease progression is defined according to RECIST 
criteria (version 1.0 [36]).  
Overall Survival OS time from the date of randomization to the date of death, regardless 
of the cause of death.  
Objective response 
rate 
ORR CR or PR as determined by the RECIST criteria  
Endpoints and 
definitions 
Time-to-Progression TTP duration from the date of first confirmed partial response or com-
plete response to disease progression or death of any reason (if death 
occurred earlier than documentation of disease progression).  
two phase III trials, only 
one fully published 
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 Health related qual-
ity-of-life 
HR-
QoL 
assessment of HR-QoL and lung cancer symptoms is based on the an-
swer of patient to FACT-L and LCSS questionnaire. FACT-L and LCS 
questionnaire should be completed at the baseline and every 6 weeks 
during the treatment and every time of follow-up during post-
treatment period. 
Results and analysis 
Analysis  
description 
Intention-to–treat (ITT) analysis, which is defined as all the randomized patients that received study 
drug treatment for at least one time. 
Two side log-rank test is the main method for comparison of the progression free survival (PFS) in 
erlotinib and chemotherapy arms, and the significance level will be 0.05. 
Characteristics Age: I 57 yrs (31 – 74) vs C 59 ( 36 – 78), <65 yrs: I 77% vs C 71% 
Sex: Males: I 41% vs C 40%, Females: I 59% vs C 60% 
Histology: Adenocarcinoma: I 88% vs C 86%, Non-adenocarcinoma: I 12% 
vs C 14% 
Smoking Status: Present or former smoker: I 28% vs C 31%, Non-smoker: I 
72% vs C 69% 
EGFR mutation type: Exon 19del: I 52% vs C 54%, L858R mutation: I 48% 
vs C 46% 
ECOG-PS: 0-1: I 91% vs C 96%, ECOG-PS 2: I 9% vs C 4% 
Disease stage: IIIB: I 13% vs C 7%, IV: I 87% vs C 93% 
Inclusion > 18 years, confirmed advanced or recurrent stage IIIB or IV NSCLC (Union 
for International Cancer Control classification version 6) with a confirmed 
activating mutation of EGFR—i.e., an exon 19 deletion or an exon 21 L858R 
point mutation. They also had measurable disease according to Response 
Evaluation Criteria In Solid Tumours (RECIST version 1.0), an Eastern Coop-
erative Oncology Group performance status of 0–2, and adequate haemato-
logical, biochemical, and organ function. 
Analysis  
population 
Exclusion if patients had uncontrolled brain metastases or had received previous sys-
temic anticancer therapy for advanced disease (although adjuvant or neo-
adjuvant therapy was allowed for non-metastatic disease in which relapse 
had occurred ≥6 months after final treatment). 
Treatment group Intervention Control 
Number of subjects 82 72 
PFS (months) 
Median 
95%CI 
 
13.1 
10.58 – 16.53 
 
4.6 
4.21 – 5.42 
OS NR NR 
ORR, n (%) 
CR 
PR 
68 (83) 
2 (2) 
66 (80) 
26 (36) 
0 (0) 
26 (36) 
Descriptive statis-
tics and estimated 
variability 
HR-QoL - - 
Comparison groups  Intervention vs Control 
HR 0.16 
95%CI 0.10 – 0.26 
Effect estimate 
per comparison 
PFS 
P value  0.0001 
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FACT-L (logistic regression analyses based 
on several covariates ) 
P- Value  
<0.0001 HR-QoL  
 
LCS score (logistic regression analyses 
based on several covariates ) 
p-Value 
<0.0001 
 
Abbreviations: AE= adverse event, WHO PS – World Health Organisation performance status, ECOG PS – Eastern 
Cooperative Oncology Group performance status, iv – intravenously; NCI-CTC – National Cancer Institute 
Common Terminology Criteria, version 3.0 (http://www.eortc.be/services/doc/ctc/ctcaev3.pdf), OS = overall 
survival, PFS = progression-free survival, ORR = overall response rate, QoL =quality-of-life, CI = confi-
dence interval, HR = hazard ratio, NR = not reached, AUC = area under the curve 
 
Table 6.1.-2: Adverse events of the OPTIMAL trial  
Grade (according to 
NCI CTC AE version 
3.0) 
Outcome, n (%) Intervention (n=83) Control (n= 72) 
Neutropenia 5 (6) 50 (69) 
Thrombocytopenia 3 (4) 46 (64) 
Anaemia 4 (5) 52 (72) 
Skin rash 61 (73) 14 (19) 
Diarrhoea 21 (25) 4 (6) 
Vomiting or nausea 1 (1) 33 (46) 
Increased ALT 31 (37) 24 (33) 
Any Grade* 
Fatigue 4 (5) 17 (24) 
Neutropenia 0 (0) 30 (42) 
Thrombocytopenia 0 (0) 29 (40) 
Anaemia 0 (0) 9 (13) 
Infection 1 (1) 0 (0) 
Skin rash 2 (2) 0 (0) 
Diarrhoea 1 (1) 0 (0) 
Stomatitis 1 (1) 0 (0) 
Vomiting or nausea 0 (0) 1 (1) 
Increased ALT 3 (4) 1 (1) 
Grade 3 or 4 
Fatigue 0 (0) 1 (1) 
Treatment-related AEs (all grades) 72 (87) 68 (94) 
Dose reduction due to a drug-related AE 5 (6) 38 (53) 
Discontinuation due to a drug-related AE 0 (0) 4 (6) 
Treatment-related SAE  2 (2) 10 (14) 
Treatment-related death 0 0 
Other outcomes 
ILD-like events 0 0 
* only AEs of any grade ≥20% are reported 
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One open-label randomised controlled trial, conducted in China, compared 
first-line therapy with erlotinib to gemcitabine + carboplatin in patients 
with stage IIIB or stage IV NSCLC. 549 patients were screened for activating 
mutations of EGFR (exon 19 deletion or exon 21 L858R point mutation), 
leading to the inclusion of 165 individuals overall. In the erlotinib group, 
one patient was excluded and in the chemotherapy group 9 patients with-
drew consent and 1 did not start treatment after randomisation, resulting in 
82 patients treated with erlotinib and in 72 patients treated with gemcit-
abine + carboplatin. More patients were females, younger than 65 years and 
non-smokers and the majority (i.e. >85%) of patients had stage IV adeno-
carcinomas and a good performance status.  
The primary outcome, progression-free survival (PFS), showed a gain of 8.5 
months for patients treated with erlotinib in comparison to those who had 
received gemcitabine + carboplatin, corresponding to a HR of 0.16 (95%CI 
0.10 – 0.26; p<0.0001). Of note, this trial was an open-label study and thus 
investigators were not blinded to the intervention the patients had been allo-
cated to. Since assessment of PFS was not subject to review by an independ-
ent committee, results might have been influenced. Moreover, 9 patients in 
the chemotherapy group withdrew consent before they had received at least 
one cycle of the assigned therapy and were therefore not considered in the 
intention-to-treat analysis. The primary cut-off date for PFS was also 
changed from July to August because 10 more events had occurred, but it is 
unclear how these events were distributed between the groups. These factors 
might have also contributed to the impressive gain in PFS. 
Pre-planned and exploratory subgroup analyses including characteristics 
such as sex, smoking status or EGFR mutation type, favoured, in terms of 
prolongation of PFS, with two exceptions always the erlotinib group. Not 
significant results were only found for the subgroup of patients with IIIB 
stage disease and for those with ECOG-PS 2, but both of these groups com-
prised only a very small number of patients.  
The overall response rates were 83% for erlotinib and 36% for chemother-
apy. The majority of these responses were partial, because only 2 patients 
(i.e. 2%) treated with erlotinib experienced complete responses, but no com-
plete response was observed in the comparison group. Overall survival was 
not yet mature, but 88 patients will be followed-up.  
Quality-of-life, assessed by the FACT-L and the LCS scores were also evalu-
ated. Significantly improved results were found for both of these scores, 
when several characteristics (e.g. performance status, smoking history and 
sex) were considered in covariate analyses. Again, since this trial was open-
label - which was justified since blinding to two different ways of admini-
strations would have proven difficult - these results might have been dis-
torted.  
Adverse events of all grades were very frequent in both groups. However, the 
side-effect profiles differed, since skin rash, a common side effect associated 
with TKI therapy, diarrhoea, increased ALT-levels and infections were more 
often observed in the erlotinib group and haematological AEs were higher in 
the chemotherapy group. AEs grade 3 or 4 occurred overall in 65% of pa-
tients in the chemotherapy and in 17% of patients treated with the TKI. 
Foremost haematological AEs of higher grades were much more common in 
the chemotherapy group, but only minor differences occurred for other AEs. 
The frequency of any serious AE (SAE) were comparable (I 12% vs C 14%), 
but those thought to be treatment-related showed also more favourable re-
one trial in China 
comparing erlotinib to 
platinum-based 
chemotherapy 
+8.5 months in PFS for 
erlotinib group 
but no independent 
review, 9 patients 
withdrew consent in the 
chemotherapy group, 
cut-off date was 
changed 
ORR: erlotinib 83% vs 
chemotherapy 36% 
mainly partial responses 
some data for 
improvements in QoL 
haematological AEs 
more common in 
chemotherapy group, 
erlotinib associated with 
higher frequency of skin 
rash and diarrhoea 
erlotinib showed 
favourable toxicity 
profile  
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sults for erlotinib (I 2% vs C 14%). Dose modifications and treatment inter-
ruptions were also more frequent in the chemotherapy group. No deaths and 
no cases of interstitial lung disease were observed.  
 
Table 6.1.-3: efficacy of the EURTAC trial 
Study title  
European Erlotinib Versus Chemotherapy (EURTAC) phase III randomised trial [21, 22] 
Study identifier ML20650 (EURTAC), NCT00446225, EURTAC-SLCG, GECP06/01, EudraCT:2006-
003568-73 
Phase III, multicentre, open-label, randomised in Spain, Italy and France, stratification 
according to ECOG status and deletion in exon 19 and mutation in exon 21 L858R 
Design 
Duration  Enrolment: February 2007 – January 2011 
Median follow-up: I 14.3 months vs C 10.7 months  
Interim analysis: August 2010 
Updated results: post-hoc analysis in January 2011 
Hypothesis Superiority 
Funding NA 
Intervention erlotinib arm received 150 mg/day orally until disease progression, 
unacceptable toxicity or death occurred. 
Treatment 
groups 
Control The following combinations of chemotherapy were allowed to be 
used per protocol for a maximum of 4 cycles: 
• Cisplatin plus docetaxel: cisplatin 75 mg/m2 intravenous (i.v.) day 
1 and docetaxel 75 mg/m2 i.v. on day 1, cycle repeated every 3 weeks
• Cisplatin plus gemcitabine: Cisplatin 75 mg/m2 i.v. on day 1 and 
gemcitabine 1250 mg/m2 on days 1 and 8. Repeat cycles every 3 
weeks. In the case of patients not eligible for treatment with cis-
platin, cisplatin could be replaced by carboplatin. The schedules 
were the following: 
• Docetaxel 75 mg/m2 day 1 and carboplatin AUC = 6 day 1, every 21 
days. 
• Gemcitabine 1000 mg/m2 days 1 and 8 and carboplatin AUC = 5
day 1, every 21 days 
Progression-free 
survival (investiga-
tor assessed) 
(primary outcome) 
PFS NA 
Overall survival OS NA 
Quality of life QoL lung cancer symptom scale (LCSS) 
Endpoints and 
definitions 
Objective response 
rate (investigator 
assessed) 
ORR NA 
Results and analysis 
Analysis  
description 
interim analysis was pre-specified after 88 out of 135 planned events had occurred. A 
Lan-DeMets alpha-spending function was used to maintain the significance level at 5%.
Analysis  
population 
Characteristics Median age (range): I 63.5 years (24 – 82 years) vs C 64.1 years
(29 - 82 years), <65 years: I 49% vs C 51% 
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Sex: Females I 68% vs C 79%, Males: I 32% vs C 21% 
Smoking Status: Current-smoker: I 4% vs C 13%, Past-smoker: I 
26% vs C 13%, Never-smoker: I 70% vs C 74% 
Histology: Adenocarcinoma: I 95% vs C 88% 
Disease stage: IIIb: I 8% vs C 7%, IV: 91% vs C 93% 
Inclusion histologic diagnosis of NSCLC, stage IV or stage IIIB with malig-
nant pleural effusion or N3 tumours not candidates for thoracic 
irradiation who present exon 19 deletions or an exon 21 L858R 
mutation in the TK domain of EGFR (histology was performed 
locally), ECOG Performance status ≤2; age >18 years; measur-
able and evaluable disease; ECOG PS 0-2; adequate bone marrow 
reserve, kidney and liver function. 
Exclusion previous treatment with chemotherapy for metastatic disease. 
The administration of neo-adjuvant or adjuvant chemotherapy 
was allowed as long as it was completed ≥ 6 months before en-
tering the study. Previous treatment with therapeutic agents 
targeting EGFR. Patients could have received radiotherapy as 
long as the irradiated lesion was not the only target lesion for 
evaluating response and as long as radiotherapy had been com-
pleted before initiating the study treatment (a 2-week period 
was recommended). 
Treatment group Intervention Control 
Number of subjects 77 76 
PFS (months), interim 
analysis 
Median 
95%CI 
 
 
9.7 
7.9 – 12.3 
 
 
5.2 
4.4 – 5.8 
PFS (months), up-
dated analysis 
Median 
95%CI 
 
 
9.7 
8.4 – 12.6 
 
 
5.2 
4.5 – 6.0 
OS (months) 
median 
95%CI 
 
22.9 
NA 
 
18.8 
NA 
ORR (%) 
95%CI 
CR (n (%)) 
PR 
SD 
PD 
54.5 
42.8 – 65.9 
2 (2.6) 
40 (51.9) 
18 (23.4) 
6 (7.8) 
10.5 
4.7 – 19.7 
0 (0) 
8 (10.5) 
42 (55.3) 
10 (13.2) 
Descriptive sta-
tistics and esti-
mated variabil-
ity 
 
 
 
 
 
 
 
 
 
 
 
 
 
QoL NA NA 
Comparison groups  Intervention vs Control 
HR (by investigator) interim analy-
sis 
0.42 
95%CI 0.27-0.64 
Effect estimate 
per comparison 
PFS 
 
P value  <0.0001 
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HR (by independent review com-
mittee), interim analysis 
0.47 
95%CI 0.28 - 0.78 
P value  0.0030 
HR, updated analysis 0.37 
95%CI 0.25 – 0.54 
P value <0.0001 
HR 0.80 
95%CI 0.47 – 1.37 
OS 
P value  0.42 
OR 10.20 
95%CI 4.32 – 24.08 
ORR 
P value  NA 
Abbreviations: NA = not available, HR = Hazard ratio, OR = Odds ratio, CI = confidence interval, AUC = area under the 
curve, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease 
 
Result of the EURTAC trial, on which the CHMP recommendation for the 
extension of indication for erlotinib was based, have not been published yet 
[21, 22]. This trial was conducted in Europe and comprised 155 patients 
with untreated stage IIIB/IV NSCLC. Only patients with EGFR activating 
mutations were enrolled and received either erlotinib or standard first-line 
platinum-based doublet chemotherapy at the discretion of the treating phy-
sician. PFS, the primary outcome, showed improved results for the erlotinib 
group, because PFS was 9.7 months in the intervention group and 5.2 
months in the control group (HR=0.42, p<0.0001). These numbers were de-
termined by the investigators and a review by an independent data monitor-
ing committee was performed only retrospectively and not for all scans. PFS 
by analysis of the independent committee was nevertheless consistent with 
that of the investigators. Due to these favourable results, the independent 
data monitory committee recommended to stop the trial. A post-hoc analysis 
(cut-off date January 2011) showed even more improved results since the 
risk of progression or death was reduced by 63%; the absolute gain in me-
dian PFS was with +4.5 months for patients in the erlotinib group un-
changed.  
The data for OS were not mature at the time of the interim analysis and did 
not show any significant differences. In addition, patients in both groups 
had already received further lines of therapy, including TKIs, at that time (I 
36% vs C 67%), thus confounding results. For the updated analysis, no de-
tailed numbers are available for OS. It is only mentioned that the number of 
patients who had either received further lines of therapy or who had crossed-
over to erlotinib had risen to 77%.  
Due to too low response rates no conclusions can be drawn for QoL. 
EURTAC: for the first 
time phase III trial 
assessing EGFR TKI in 
European population 
erlotinib versus 
standard-
chemotherapies 
PFS significantly 
improved for erlotinib at 
interim analysis:  
HR = 0.42 
OS was not mature, but 
cross-over to EGFR TKI 
therapy will confound 
results 
no data for QoL 
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AEs were very common in both groups, because nearly every patient experi-
enced at least one AE. The most frequent ones in the erlotinib group were 
skin rash and diarrhoea and asthenia and anaemia in the chemotherapy 
group. AEs of grade ≥3 were observed in 66% in the chemotherapy group 
and in 41% in the TKI group, but no difference in terms of SAEs existed be-
tween the two groups. However, 6% of SAE in the erlotinib group were con-
sidered as treatment-related and one treatment-related death was observed 
in that group, comparable numbers are missing for the chemotherapy group. 
Of note, treatment duration in the erlotinib group was considerably longer 
than in the chemotherapy group, which might explain, for example, higher 
numbers of SAE in the erlotinib group [21].  
 
Table 6.1-4: Adverse events of the EURTAC trial  [21]  
Only AEs any grade ≥20% are displayed 
 
higher grade AEs more 
frequent in 
chemotherapy group, 
but no differences in 
severe AEs… 
..due to longer 
treatment duration in 
erlotinib group? 
Grade Outcome (%) Intervention (n=75) Control (n= 74) 
Overall 72 (96) 73 (99) 
Neutropenia 0 (0) 27 (37) 
Anaemia 8 (11) 34 (46) 
Skin rash 37 (49) 1 (1) 
Diarrhoea 43 (57) 14 (19) 
Nausea 17 (23) 30 (41) 
Asthenia 40 (53) 51 (69) 
Vomiting 10 (13) 16 (22) 
Constipation 6 (8) 16 (22) 
Cough 34 (45) 26 (35) 
Dyspnoea 31 (41) 19 (26) 
Any Grade 
Decreased appetite  21 (28) 25 (34) 
Grade ≥3  Overall 31 (41) 49 (66) 
Grade 5 Overall 7 (9) 4 (5) 
SAE NA (27) NA (26) 
AEs leading to dose modifica-
tion/interruption  
20 (27) 39 (53) 
AEs leading to discontinuation  NA (12) NA (15) 
Treatment-related SAE  5 (6) NA 
Others 
Treatment-related death 1 (1) NA 
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6.2 Efficacy and safety - further studies 
Rosell et al. [24] conducted a screening study in Spain. Of 2,105 patients, 
EGFR mutations were detected in 350 (16.6%) individuals. Of these, 217 pa-
tients were treated with erlotinib, either as first-line or as second-line ther-
apy. Response was assessed in 197 patients of whom the majority showed 
partial responses (58.4%). Complete responses were observed in 12.2%. It is 
unclear though how these numbers can be allotted to the different lines of 
therapies. Specific results for first-line therapy are available for PFS (14.0 
months, 95%CI 9.7 – 18.3 months) and for OS (28.0 months, 95%CI 22.7 – 
33 months). Most common AEs were comparable to those reported in the 
phase III studies (skin rash: 70%, diarrhoea: 44%) but were mainly of grade 
1 or 2. Toxic skin effects of grade 3 were observed in 7% and diarrhoea of 
grade 3 in 4% of patients. One case of interstitial lung disease occurred.  
A pooled analysis evaluated EGFR-TKIs (erlotinib and gefitinib) and che-
motherapy in patients with EGFR mutations [23]. Prospective and retro-
spective studies were included without restrictions to a certain line of ther-
apy. Better PFS results were shown for both EGFR TKIs than for chemo-
therapy regardless of the line of therapy, but consistent findings were ob-
served if predominantly untreated patients were considered. For this indica-
tion median PFS was 12.5 months for erlotinib, 9.9 months for gefitinib and 
6.0 months for chemotherapy.   
7 Estimated costs  
No price estimates are available yet for Austria, but in Germany one package 
of 30 tablets erlotinib 150mg, which equals the monthly dosage, is € 2,900 
[37]. Since erlotinib replaces chemotherapy, this would be the only costs for 
first-line therapy. In addition, due to the oral administration and fewer side-
effects, potential savings might incur since hospital admissions might be re-
duced. On the other hand, costs for EGFR testing prior to erlotinib therapy 
have to be taken into account, but no information on the associated costs is 
available.  
8 On-going studies 
One on-going phase III study assessing first-line therapy in erlotinib in pa-
tients with NSCLC and EGFR activating mutations was found at Clinical-
Trials.Gov: 
NCT01342965: evaluates erlotinib versus gemcitabine/cisplatin as the first-
line treatment for stage IIIB/IV NSCLC patients with mutations in the tyro-
sine kinase domain of EGFR in their tumour. Estimated study completion 
date is February 2013.  
screening study 
including first and 
second-line erlotinib 
therapy 
AEs similar to phase III 
studies 
pooled analysis 
confirmed better results 
in PFS for first-line 
EGFR TKI therapy 
no costs estimates for 
Austria 
in Germany: € 2,900 for 
one month therapy 
savings due to fewer 
AEs and oral 
administration possible 
one on-going phase III 
study for the 
investigated indication 
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No further phase III trial was identified for this indication on the EU Clini-
cal Trials Register, but erlotinib is under investigation in phase II trials in 
combination with other experimental drugs for NSCLC in general (e.g. OSI-
906, U3-1287, MetMAb). 
Other on-going phase III studies evaluate erlotinib for cancers including 
hepatocellular carcinoma, colorectal cancer and oesophageal cancer.   
9 Commentary  
In July 2011, the CHMP recommended to extend the indication of erlotinib 
to first-line therapy for locally advanced/metastatic NSCLC with EGFR ac-
tivating mutations [18]. Two phase III studies investigated this indication 
[20, 21]. One was conducted in China [20], whereas the EURTAC trial was 
conducted in European countries and assessed, for the first time, efficacy of 
an EGFR-TKI for the treatment of lung cancer in Caucasian patients. In 
both trials, the comparator(s) used were platinum-based doublet chemo-
therapies, currently the standard-of-care for first-line therapy of NSCLC. 
PFS was significantly improved for patients treated with erlotinib, yielding 
a risk reduction of 53% to 84%. More favourable outcomes for tumour re-
sponse, mainly partial responses, were also found for these patients. How-
ever, no reliable statements can be made on the impact of erlotinib on OS, 
either due to cross-over or immature data. QoL related outcomes were re-
ported in only one of these trials [20], showing significant improvements for 
patients treated with erlotinib, but these results are potentially compro-
mised due to the study design (open label). However, partial responses of 
50%-80% (in comparison to 10% -36% in the chemotherapy group), fewer 
SAEs and the oral administration of erlotinib give support that improve-
ments in QoL can be expected.  
Overall AEs were very common in the erlotinib and in the chemotherapy 
group, affecting nearly all patients. Distinct differences in the toxicity pro-
files of erlotinib and chemotherapeutic regimens exist, because skin rash (in 
up to 73%) and diarrhoea (in up to 57%) were more frequent in the erlotinib 
group, whereas more patients treated with chemotherapy experienced 
haematologic side-effects. A higher proportion of individuals had grade ≥3 
AEs in the platinum-based doublet groups and treatment-related SAEs were 
also more often observed in this group [21]. Similarly, dose modifications or 
treatment discontinuations were necessary in considerably fewer patients 
treated with erlotinib than in those receiving chemotherapy.  
Erlotinib will be, besides gefitinib, the second EGFR-TKI licensed for the 
first-line therapy of advanced/metastatic NSCLC with EGFR activating mu-
tations in Europe. Both drugs have been incorporated into European Guide-
lines [3, 38]. In contrast, neither of these agents has received marketing au-
thorization for the first-line therapy of NSCLC in the U.S., but the Ameri-
can Society of Clinical Oncology adopted nevertheless a provisional opinion, 
recommending EGFR testing in the first-line setting [5]. Both drugs are 
EGFR-TKIs and might be used interchangeably [3, 8], but since no head-to-
head trials comparing these two drugs have been performed, it is unclear if 
one drug offers specific advantages over the other.  
erlotinib also under 
investigation for other 
cancers and as 
combination therapy for 
NSCLC  
extension of indication 
to first-line setting 
recommended in July 
2011 
improvements in PFS 
and ORR 
 
impact on OS unclear 
improvements in QoL 
likely 
more favourable toxicity 
profile than 
chemotherapies 
erlotinib is after 
gefitinib 2nd EGFR TKI 
licensed for first-line 
NSCLC therapy 
 
differences between 
these drugs?  
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For both drugs, issues relating to identification of eligible patients by EGFR 
testing need to be addressed. Several testing methods are available to date 
(e.g. Sanger method, Cobas® 4800 EGFR mutation test, High Resolution 
Melt, TheraScreen EGFR 29 by DxS Ltd) which might have different accu-
racies. Thus a comparison of these tests might be useful in determining the 
best method [6]. Even though EGFR mutation testing is a prerequisite for 
EGFR-TKI therapy, the evidence is a bit patchy if testing is only indicated 
for patients with adenocarcinomas, non-squamous carcinomas or if it should 
be performed regardless of histology [3, 5, 8, 39]. In any case, EGFR testing 
should be performed only within quality-assurance programmes.   
Another issue is resistance to EGFR TKIs which eventually develops in all 
patients treated with these drugs. In both phase III studies enrolment was 
based on the presence of EGFR activating mutations, but testing for muta-
tions which confer resistance, for example mutation T790M in exon 20, an 
“acquired resistance mutation”, where not considered [5, 6]. Despite the fact 
that presence of T790M mutations are associated with a short PFS [2], the 
European Society for Medical Oncology state that patients should not be 
precluded from EGFR-TKI therapy even if T790M mutations are detected 
[3]. This might be based on the fact that even if patients develop second re-
sistance to erlotinib, this resistance might be lost and TKI therapy might be-
come effective again after TKI treatment was stopped [6]. Thus monitoring 
of the tumours’ genotype during therapy might be indicated. Even though 
material from cytology cell blocks is usually required for determining EGFR 
mutations [5], the material retrieved by biopsies is sometimes not sufficient 
for a complete molecular analysis [40]. Therefore other approaches for the 
determination of EGFR activating mutations such as cytological smears or 
circulating tumour cells from blood samples have been investigated [40, 41]. 
In summary, due to gains in PFS and a more favourable toxicity profile in 
comparison to platinum-based chemotherapy, EGFR-TKIs have increas-
ingly become standard first-line therapy for patients with activating EGFR 
mutations and advanced/metastatic NSCLC. Open questions mainly con-
cern EGFR testing and determinants of resistance. 
 
 
 
 
to date no comparison 
of different EGFR 
mutation tests available 
for all patients or based 
on histological cancer 
type?  
tests for resistance? 
EGFR-TKIs have become 
standard of care for 
first-line therapy of 
NSCLC with activating 
EGFR mutations 
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